17,261 trials
Non-small Cell Lung Cancer
Primary: Presence or Absence of a Dose Limiting Toxicity (DLT) of ALT-803 in Combination With Nivolumab — 3; 3; 6; 8 Participants
Hepatocellular Carcinoma
Primary: Objective Response Rate (ORR) — 22.5; 34.3 Percentage of participants
Cutaneous Neurofibroma · Neurofibromatosis 1
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 35; 36; 49 Participants
Biliary Tract Cancer
Primary: Phase Ib: Incidence of Dose-limiting Toxicities (DLTs) of Drug Combination Nanoliposomal-Irinotecan, 5-fluorouracil, Leucovorin and Nivolumab — 4 Participants
Dry Eye Disease
Primary: Mean Change From Baseline to Week 8 in Symptoms of Dry Eye Assessed by Symptom Assessment in Dry Eye (SANDE) Global Score — -19.6; -20.7; -15.5 score on a scale — p==0.076
Prostate Cancer
Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months
Colorectal Cancer
Primary: Major Pathological Response (MPR) Rate — 89.7 Percentage of Participants
SARS-CoV-2
Primary: Time to Sustained Alleviation or Resolution of COVID-19 Symptoms — 5.2; 6.1 days
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24 — -9.5 scores on scale
Postherpetic Neuralgia
Primary: Change From Baseline (Week 2 of the Run-in Period) in Average Daily Pain Score (ADPS) — -1.62; -2.42 score on a scale — p=0.120
Colorectal Cancer Metastatic
Primary: Primary - Progression-free Survival (PFS) — 9.2; 9.2 Months of progression-free survival
Sarcoma
Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants
Cholera
Primary: Level of Antibody Titers in Serum — 76; 2671 Vibriocidal antibody titer
Atopic Dermatitis
Primary: Percent Change in Eczema Area and Severity Index (EASI) Score — -61.15; -57.05; -64.27; -51.42 percent of change — p=0.0090
Trigger Point Pain, Myofascial
Primary: Pain Scores on the Visual Analog Scale — 51; 55; 40; 42 Pain Scores on the Visual Analog Scale